| DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology VT DeVita, TS Lawrence, SA Rosenberg Lippincott Williams & Wilkins, 2008 | 7672* | 2008 |
| Cancer regression in patients after transfer of genetically engineered lymphocytes RA Morgan, ME Dudley, JR Wunderlich, MS Hughes, JC Yang, ... Science 314 (5796), 126-129, 2006 | 4228 | 2006 |
| Cancer immunotherapy: moving beyond current vaccines SA Rosenberg, JC Yang, NP Restifo Nature medicine 10 (9), 909-915, 2004 | 3832 | 2004 |
| Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes ME Dudley, JR Wunderlich, PF Robbins, JC Yang, P Hwu, ... Science 298 (5594), 850-854, 2002 | 3782 | 2002 |
| A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone SA Rosenberg, MT Lotze, LM Muul, AE Chang, FP Avis, S Leitman, ... New England Journal of Medicine 316 (15), 889-897, 1987 | 3651 | 1987 |
| A randomized trial of bevacizumab, an anti–vascular endothelial growth factor antibody, for metastatic renal cancer JC Yang, L Haworth, RM Sherry, P Hwu, DJ Schwartzentruber, ... New England Journal of Medicine 349 (5), 427-434, 2003 | 3603 | 2003 |
| Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer SA Rosenberg, MT Lotze, LM Muul, S Leitman, AE Chang, ... New England journal of medicine 313 (23), 1485-1492, 1985 | 3485 | 1985 |
| T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial DW Lee, JN Kochenderfer, M Stetler-Stevenson, YK Cui, C Delbrook, ... The Lancet 385 (9967), 517-528, 2015 | 3299 | 2015 |
| Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. SA Rosenberg, BS Packard, PM Aebersold, D Solomon, SL Topalian, ... The New England journal of medicine 319 (25), 1676-1680, 1988 | 3204 | 1988 |
| Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 RA Morgan, JC Yang, M Kitano, ME Dudley, CM Laurencot, ... Molecular therapy 18 (4), 843-851, 2010 | 2981 | 2010 |
| Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy SA Rosenberg, JC Yang, RM Sherry, US Kammula, MS Hughes, ... Clinical cancer research 17 (13), 4550-4557, 2011 | 2720 | 2011 |
| Adoptive cell transfer as personalized immunotherapy for human cancer SA Rosenberg, NP Restifo Science 348 (6230), 62-68, 2015 | 2717 | 2015 |
| A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes SA Rosenberg, P Spiess, R Lafreniere Science 233 (4770), 1318-1321, 1986 | 2622 | 1986 |
| High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 MB Atkins, MT Lotze, JP Dutcher, RI Fisher, G Weiss, K Margolin, ... Journal of clinical oncology 17 (7), 2105-2105, 1999 | 2538 | 1999 |
| Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer E Tran, S Turcotte, A Gros, PF Robbins, YC Lu, ME Dudley, ... Science 344 (6184), 641-645, 2014 | 2527 | 2014 |
| Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma SA Rosenberg, JC Yang, DJ Schwartzentruber, P Hwu, FM Marincola, ... Nature medicine 4 (3), 321-327, 1998 | 2264 | 1998 |
| T lymphocyte-directed gene therapy for ADA− SCID: initial trial results after 4 years RM Blaese, KW Culver, AD Miller, CS Carter, T Fleisher, M Clerici, ... Science 270 (5235), 475-480, 1995 | 2264 | 1995 |
| Adoptive cell transfer: a clinical path to effective cancer immunotherapy SA Rosenberg, NP Restifo, JC Yang, RA Morgan, ME Dudley Nature Reviews Cancer 8 (4), 299-308, 2008 | 2167 | 2008 |
| Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma ME Dudley, JR Wunderlich, JC Yang, RM Sherry, SL Topalian, NP Restifo, ... Journal of clinical oncology 23 (10), 2346-2357, 2005 | 2165 | 2005 |
| Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired M Ahmadzadeh, LA Johnson, B Heemskerk, JR Wunderlich, ME Dudley, ... Blood, The Journal of the American Society of Hematology 114 (8), 1537-1544, 2009 | 2161 | 2009 |